What gives ,
1.Merck licensing deal
2.Merck buyout
Surely if the 1st line upcoming NSCLC data is good, Merck stumps up.Big Pharma don’t like sharing,this is beginning to look like a must have for Merck,they’ll want to tie the technology up one way or another.
Ann: New & significant data from AIPAC phase 2b trial in MBC, page-22
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
-0.015(4.55%) |
Mkt cap ! $480.0M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 32.5¢ | 31.3¢ | $109.3K | 344.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 101932 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 30193 | 10 |
View Market Depth
| Last trade - 10.29am 18/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |